After resection of stage III melanoma, adjuvant immunotherapy has previously been associated with a reduction in the risk for recurrence, which has proven to be common even with tumor-free margins, but a new phase 3 study shows that immunotherapy before surgery reduces this risk.
Compared with postsurgical immunotherapy, nivolumab (Opdivo, Bristol Myers Squibb) plus ipilimumab (Yervoy, Bristol Myers Squibb) before surgery followed by adjuvant nivolumab after surgery, if needed, reduced